Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis

What Duration of Intravenous Antibiotic Therapy Should be Used in the Treatment of Infective Exacerbations of Cystic Fibrosis Chronically Colonised With Pseudomonas Aeruginosa

Cystic Fibrosis patients attending with infective exacerbations will be enrolled into the study. The trial is a double blinded, randomised trial with patients randomised to 10,14 or 21 days of antibiotic therapy, comprising of tobramycin and either ceftazidime or meropenem.

Inclusion Criteria:

• 16 years or older
• Diagnosis of Cystic Fibrosis
• Presenting with Infective exacerbation

Exclusion Criteria:

• Unable to give consent
• Allergy to study medications
• Intolerance of aminoglycoside antibiotics
• Pseudomonas resistant to study antibiotics
• On the active transplant list or FEV1<20% predicted
• Pregnancy/breast-feeding
• Co-existent ABPA requiring a change in treatment
• Co-existent mycobacterial infection
• A previous participant in the study